Carbon

Our long term goal is to be carbon-neutral across our value chain by 2050. We are reducing operational emissions and engaging with suppliers and consumers to cut emissions associated with sourcing raw materials and using our products. This means not only managing emissions in the value chain, but also looking at more resource-efficient technologies to make our products.

Product impacts

We have been working with the Carbon Trust since 2011 to measure and certify the carbon footprints of our 40 biggest selling products to identify where we can make the most effective reductions from emissions associated with our products.

Operational impacts

Reducing energy use, and the carbon emissions associated with the energy that we purchase, is an important focus of our programme to cut environmental impacts. We are investing in infrastructure such as wind turbines to generate renewable energy, and using waste as fuel for energy.

Our supply chain

Working with our suppliers to help them reduce their carbon emissions is critical to achieving our carbon goals. In 2014, we collected carbon,water and waste data from over 200 of our largest materials suppliers, covering over £1 billion of our spending on raw materials used in manufacturing and R&D.

In 2014 we also launched the GSK Supplie rInnovation Exchange. Through this online forum,around 100 suppliers collaborated to share practical ideas about improving energy efficiency and reducing water use. Suppliers have used this insight to make improvements in their operations.

Use of our products

Use of our products, such as metered dose inhalers, accounts for 46% of carbon emissions across our value chain. In 2014 the Carbon Trust certified the carbon footprints of three of our respiratory products according to the Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices. This enables us to understand the carbon footprint reduction benefitsof our newer dry powder inhalers, versus our older inhalers.

Complete the Cycle

Our Complete the Cycle initiative encourages patients and customers to return their old respiratory inhalers to participating pharmacies which are then sent back to us to be recycled. This reduces waste sent to landfill as well as prevents the remaining propellant in used inhalers being released as greenhouse gases, as we collect it when crushing the cans for aluminum which is recycled.

External benchmarking

Recertified in 2014, GSK remains the only pharmaceutical company to have achieved the Carbon Trust’s Carbon Standard and Water Standard for cutting carbon emissions and water use across our operations globally.

We retained our position in the CDP’s FTSE 350 Climate Disclosure Leadership Index for the seventh year. GSK is one of only two pharmaceutical companies to be included in the index in recognition of the amount and quality of climate change data we disclosed.